Insulet Revenue 2012-2026 | PODD
Insulet annual/quarterly revenue history and growth rate from 2012 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Insulet revenue for the quarter ending March 31, 2026 was $0.762B, a 33.87% increase year-over-year.
- Insulet revenue for the twelve months ending March 31, 2026 was $2.901B, a 31.92% increase year-over-year.
- Insulet annual revenue for 2025 was $2.708B, a 30.73% increase from 2024.
- Insulet annual revenue for 2024 was $2.072B, a 22.07% increase from 2023.
- Insulet annual revenue for 2023 was $1.697B, a 30.02% increase from 2022.
|
Insulet Annual Revenue (Millions of US $) |
|
|---|---|
| 2025 | $2,708 |
| 2024 | $2,072 |
| 2023 | $1,697 |
| 2022 | $1,305 |
| 2021 | $1,099 |
| 2020 | $904 |
| 2019 | $738 |
| 2018 | $564 |
| 2017 | $464 |
| 2016 | $367 |
| 2015 | $264 |
| 2014 | $231 |
| 2013 | $247 |
| 2012 | $211 |
| 2011 | $152 |
|
Insulet Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2026-03-31 | $762 |
| 2025-12-31 | $784 |
| 2025-09-30 | $706 |
| 2025-06-30 | $649 |
| 2025-03-31 | $569 |
| 2024-12-31 | $598 |
| 2024-09-30 | $544 |
| 2024-06-30 | $489 |
| 2024-03-31 | $442 |
| 2023-12-31 | $510 |
| 2023-09-30 | $433 |
| 2023-06-30 | $397 |
| 2023-03-31 | $358 |
| 2022-12-31 | $370 |
| 2022-09-30 | $341 |
| 2022-06-30 | $299 |
| 2022-03-31 | $295 |
| 2021-12-31 | $308 |
| 2021-09-30 | $276 |
| 2021-06-30 | $263 |
| 2021-03-31 | $252 |
| 2020-12-31 | $246 |
| 2020-09-30 | $234 |
| 2020-06-30 | $226 |
| 2020-03-31 | $198 |
| 2019-12-31 | $209 |
| 2019-09-30 | $192 |
| 2019-06-30 | $177 |
| 2019-03-31 | $160 |
| 2018-12-31 | $165 |
| 2018-09-30 | $151 |
| 2018-06-30 | $124 |
| 2018-03-31 | $124 |
| 2017-12-31 | $131 |
| 2017-09-30 | $122 |
| 2017-06-30 | $110 |
| 2017-03-31 | $102 |
| 2016-12-31 | $104 |
| 2016-09-30 | $95 |
| 2016-06-30 | $87 |
| 2016-03-31 | $81 |
| 2015-12-31 | $84 |
| 2015-09-30 | $71 |
| 2015-06-30 | $61 |
| 2015-03-31 | $48 |
| 2014-12-31 | $15 |
| 2014-09-30 | $75 |
| 2014-06-30 | $72 |
| 2014-03-31 | $69 |
| 2013-12-31 | $69 |
| 2013-09-30 | $61 |
| 2013-06-30 | $60 |
| 2013-03-31 | $57 |
| 2012-12-31 | $58 |
| 2012-09-30 | $55 |
| 2012-06-30 | $51 |
| 2012-03-31 | $48 |
| 2011-12-31 | $47 |
| 2011-09-30 | $45 |
| 2011-06-30 | $32 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $13.640B | $2.708B |
| Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $174.688B | 19.48 |
| Stryker (SYK) | United States | $129.889B | 24.88 |
| Medtronic (MDT) | Ireland | $111.968B | 15.57 |
| EssilorLuxottica (ESLOY) | France | $107.724B | 0.00 |
| Boston Scientific (BSX) | United States | $91.831B | 20.26 |
| Medline (MDLN) | United States | $59.904B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.712B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $33.391B | 15.98 |
| ResMed (RMD) | United States | $33.341B | 22.26 |
| Agilent Technologies (A) | United States | $32.516B | 20.44 |
| Koninklijke Philips (PHG) | Netherlands | $27.260B | 16.18 |
| Terumo (TRUMY) | Japan | $19.854B | 23.21 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.025B | 11.36 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.227B | 0.00 |
| Baxter (BAX) | United States | $8.854B | 7.56 |
| Sunny Optical Technology (SNPTF) | China | $8.381B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.537B | 28.15 |
| Demant (WILYY) | Denmark | $6.395B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $5.247B | 15.90 |
| Envista Holdings (NVST) | United States | $4.301B | 21.99 |
| BillionToOne (BLLN) | United States | $3.729B | 0.00 |
| DiaSorin S.p.A (DSRLF) | Italy | $3.666B | 0.00 |
| ICU Medical (ICUI) | United States | $3.141B | 20.47 |
| Prestige Consumer Healthcare (PBH) | United States | $2.676B | 12.62 |
| Haemonetics (HAE) | United States | $2.664B | 11.65 |
| LeMaitre Vascular (LMAT) | United States | $2.611B | 48.16 |
| Phibro Animal Health (PAHC) | United States | $2.347B | 20.67 |
| GN Store Nord (GNNDY) | Denmark | $2.270B | 21.90 |
| Neogen (NEOG) | United States | $2.050B | 44.86 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $2.028B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $1.794B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.654B | 32.89 |
| Curaleaf Holdings (CURLF) | Canada | $1.584B | 0.00 |
| Perrigo (PRGO) | Ireland | $1.495B | 3.96 |
| AtriCure (ATRC) | United States | $1.429B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.386B | 15.91 |
| Kestra Medical Technologies (KMTS) | United States | $1.043B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.953B | 164.50 |
| QuidelOrtho (QDEL) | United States | $0.943B | 6.53 |
| Lumexa Imaging Holdings (LMRI) | United States | $0.896B | 0.00 |
| InMode (INMD) | Israel | $0.857B | 9.40 |
| Omeros (OMER) | United States | $0.827B | 6.49 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.789B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.766B | 0.00 |
| CeriBell (CBLL) | United States | $0.683B | 0.00 |
| Brainsway (BWAY) | Israel | $0.546B | 55.68 |
| Valneva SE (VALN) | France | $0.532B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.468B | 11.18 |
| Cresco Labs (CRLBF) | United States | $0.458B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.424B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.415B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.367B | 25.70 |
| SNDL (SNDL) | Canada | $0.366B | 0.00 |
| Cerus (CERS) | United States | $0.363B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.311B | 126.00 |
| Evolus (EOLS) | United States | $0.278B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.259B | 0.00 |
| MacroGenics (MGNX) | United States | $0.229B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Accendra Health (ACH) | United States | $0.215B | 2.96 |
| Utah Medical Products (UTMD) | United States | $0.210B | 18.94 |
| High Tide (HITI) | Canada | $0.205B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.205B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.194B | 57.17 |
| TerrAscend (TSNDF) | Canada | $0.193B | 0.00 |
| Organigram Global (OGI) | Canada | $0.191B | 0.00 |
| Apyx Medical (APYX) | United States | $0.166B | 0.00 |
| Quanterix (QTRX) | United States | $0.158B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.152B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.145B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.143B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.133B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.53 |
| Jushi Holdings (JUSHF) | United States | $0.101B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.090B | 11.73 |
| Exagen (XGN) | United States | $0.073B | 0.00 |
| Sharps Technology (STSS) | United States | $0.065B | 0.00 |
| ImmuCell (ICCC) | United States | $0.064B | 0.00 |
| Biote (BTMD) | United States | $0.063B | 3.46 |
| INLIF (INLF) | China | $0.053B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.038B | 0.00 |
| Veru (VERU) | United States | $0.038B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| Nephros (NEPH) | United States | $0.032B | 26.91 |
| United-Guardian (UG) | United States | $0.030B | 14.23 |
| Bonk (BNKK) | United States | $0.021B | 0.00 |
| Jin Medical (ZJYL) | China | $0.018B | 0.00 |
| Modular Medical (MODD) | United States | $0.013B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Agape ATP (ATPC) | $0.003B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.001B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |